Compare · IMNN vs NVO
IMNN vs NVO
Side-by-side comparison of Imunon Inc. (IMNN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMNN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 28974.9x IMNN ($7.7M).
- IMNN has been more active in the news (10 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for IMNN).
- Company
- Imunon Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $7.7M
- $222.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IMNN
- Executive Chairman of Board Tardugno Michael H was granted 4,410 shares, increasing direct ownership by 7% to 64,396 units (SEC Form 4)
- SEC Form 3 filed by new insider Blacher Joshua
- General Counsel and Corp Sec Eylward Susan was granted 920 shares and sold $1,730 worth of shares (920 units at $1.88) (SEC Form 4)
- Chief Medical Officer Faller Douglas Vincent was granted 1,308 shares, increasing direct ownership by 6% to 23,204 units (SEC Form 4)
- President and CEO Lindborg Stacy was granted 2,534 shares, increasing direct ownership by 3% to 76,722 units (SEC Form 4)
- Imunon Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Medical Officer Faller Douglas Vincent was granted 21,896 shares (SEC Form 4)
- General Counsel and Corp Sec Eylward Susan was granted 14,696 shares and sold $20,674 worth of shares (11,800 units at $1.75) (SEC Form 4)
- Executive Chairman of Board Tardugno Michael H was granted 42,519 shares, increasing direct ownership by 243% to 59,986 units (SEC Form 4)
- President and CEO Lindborg Stacy was granted 67,150 shares, increasing direct ownership by 954% to 74,188 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S